HOME >> BIOLOGY >> NEWS
New finding may identify unknown agents of mad-cow disease

Researchers at the University of Illinois at Chicago, working with yeast, have made the startling finding that the presence of one prion protein can spark the formation of other unrelated prions similar to the protein thought to cause mad cow and other diseases of mammals and man.

The researchers also devised a screening test that can be used to pinpoint unidentified prions, making it the first such genetic assay for these mysterious biological agents.

The findings are reported in the July 27 issue of the journal Cell by UIC biology professor Susan Liebman and three co-workers. A prion, the causative agent of "mad cow" disease and human Creutzfeldt-Jakob disease, is an improperly folded protein molecule that clumps together and corrupts other, healthy molecules of the same protein to do likewise, in domino fashion. When the cell divides, the corrupt protein is contained in both daughter cells, where it seeds the process again. Prions are thus infective and heritable without containing DNA or RNA as viruses do.

According to Liebman, the finding that one prion can help start the chain reaction in another, totally different protein is important, because much more is known about how prions propagate than about how they first appearwhich also bears on public health concerns. Most cases of Creutzfeldt-Jakob disease, a neurodegenerative disease in humans, have no known origin, she said.

Its a great concern that humans can acquire CJD from infected cattle, but far, far more cases arise spontaneously, Liebman said.

Liebmans team devised a genetic screen for a trait in yeast that sparked the appearance of a known yeast prion. Their test identified the protein responsible for this trait and also pointed to nine other yeast prion-like proteins causing the same trait. These new prion candidates were found to contain prion-like regions in their protein chains.

We think what we have is a general test for new prions, Liebman s
'"/>

Contact: Bill Burton
burton@uic.edu
312-996-2269
University of Illinois at Chicago
26-Jul-2001


Page: 1 2

Related biology news :

1. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
2. Virginia Tech researchers to release findings on Smith River Project
3. New HIV findings
4. Stanford researchers findings may shed light on common, deadly birth defect
5. Briggs takes to the molecular level Darwins findings on plants sensing the direction of light
6. Brain serotonin enzyme finding might explain psychiatric disorders
7. Why does cloning create abnormalities? Scientists take a step towards finding out
8. TIGR president discusses significance of finding anthrax toxin
9. Latest findings on PCBs to be subject of June workshop at Illinois
10. Chlamydia in men now also linked to infertility new findings
11. Purdue scientists finding ways to outsmart crop-damaging bugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New finding may identify unknown agents mad cow disease

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: